The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice

被引:18
作者
Uhr, M [1 ]
Ebinger, M [1 ]
Rosenhagen, MC [1 ]
Grauer, MT [1 ]
机构
[1] Max Planck Inst Psychiat, D-80804 Munich, Germany
关键词
multiple drug resistance; knock-out mice; P-glycoprotein; blood-brain barrier; budipine; abcb1;
D O I
10.1016/j.neulet.2005.04.020
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
P-glycoprotein, a product of the ABCB1 gene, is a plasma membrane transporter that exports certain drugs as well as endogenous substances against a concentration gradient in the intestines, kidney and testes. It also constitutes an important part of the blood-brain barrier, where it exports its substrates out of the brain back into the circulation. To investigate whether the uptake of the anti-Parkinson drug budipine into the brain is mediated by P-glycoprotein, abeblab(-/-) double knock-out mice and wild-type control mice received budipine continuously over 11 days via implanted osmotic infusion pumps at the rate of 30 ug over 24h. Concentrations of the drug in plasma, brain, and organs were measured with HPLC. Budipine concentrations in the abcb1ab knock-out animals were 3.1 times higher than in control mice. This study confirms the important role P-gp plays at the blood-brain barrier and shows that budipine is a substrate of P-gp. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 19 条
[1]  
Eltze M, 1999, J NEURAL TRANSM-SUPP, P83
[2]   Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain [J].
Fisher, A ;
Starr, MS .
BRAIN RESEARCH, 2000, 868 (02) :268-274
[3]   Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease [J].
Furuno, T ;
Landi, MT ;
Ceroni, M ;
Caporaso, N ;
Bernucci, I ;
Nappi, G ;
Martignoni, E ;
Schaeffeler, E ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2002, 12 (07) :529-534
[4]   St John's Wort increases expression of P-glycoprotein: Implications for drug interactions [J].
Hennessy, M ;
Kelleher, D ;
Spiers, JP ;
Barry, M ;
Kavanagh, P ;
Back, D ;
Mulcahy, F ;
Feely, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (01) :75-82
[5]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[6]  
Kerb R., 2001, Pharmacogenomics Journal, V1, P204
[7]   THE ANTIPARKINSONIAN AGENT BUDIPINE IS AN N-METHYL-D-ASPARTATE ANTAGONIST [J].
KLOCKGETHER, T ;
JACOBSEN, P ;
LOSCHMANN, PA ;
TURSKI, L .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1993, 5 (02) :101-106
[8]   P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain [J].
Potschka, H ;
Fedrowitz, M ;
Löscher, W .
NEUROREPORT, 2001, 12 (16) :3557-3560
[9]   Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen [J].
Przuntek, H ;
Bittkau, S ;
Bliesath, H ;
Büttner, U ;
Fuchs, G ;
Glass, J ;
Haller, H ;
Klockgether, T ;
Kraus, P ;
Lachenmayer, L ;
Müller, D ;
Müller, T ;
Rathay, B ;
Sgonina, J ;
Steinijans, V ;
Teshmar, E ;
Ulm, G ;
Volc, D .
ARCHIVES OF NEUROLOGY, 2002, 59 (05) :803-806
[10]   A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression [J].
Roberts R.L. ;
Joyce P.R. ;
Mulder R.T. ;
Begg E.J. ;
Kennedy M.A. .
The Pharmacogenomics Journal, 2002, 2 (3) :191-196